Verastem, Inc VSTM Stock Price, Quote & News

According to the current price, Verastem is 21.04% away from the 52-week high. The 8 analysts offering price forecasts for Verastem have a median target of 4.50, with a high estimate of 8.00 and a low estimate of 3.00. The median estimate represents a 9.93 difference from the last price of 0.45. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination wi… The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods.

The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank. Join thousands of traders who make more informed decisions with our premium features.

During the last day, the stock moved $0.0395 between high and low, or 9.39%. For the last week the stock has had daily average volatility of 12.28%. Verastem exhibits a price/sales ratio which is less than the industry average for drugs stocks listed on the NASDAQ. Verastem exhibits a price/book ratio which is within a 15% range of the industry average for drugs stocks listed on the NASDAQ.

Explore more features and data

Wainwright maintained a Buy rating on Verastem (VSTM – Research Report), with a price target of $3.00. The company’s shares closed last Friday at $0.39.Lee CFA covers the … This stock may move very much during the day and with periodic low trading volume this stock is considered to be “very high risk”.

Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services.

Time Founder’s Wasabi Technologies Aims At Amazon In $70B Cloud Market

All other current web features including annual reports, price sensitive announcements, dividends and earnings transcripts are free to use here on our web app. JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries. None of these entities provide legal, tax, or accounting advice. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.

• The technique has proven to be very useful for finding positive surprises.
• This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.
• An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s.
• 5 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Verastem in the last twelve months.
• Verastem has a short interest ratio (“days to cover”) of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
• Long term indicators fully support a continuation of the trend.

The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure. Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.

VSTM Verastem, Inc.Stock Price & Overview

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Verastem stock was originally listed at a price of $11.09 in Jan 27, 2012.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. An affiliate of Public may be “testing the waters” and considering making an offering of securities under Tier 2 of Regulation A. No money or other consideration is being solicited and, if sent in response, will not be accepted. No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC. An indication of interest to purchase securities involves no obligation or commitment of any kind.

Price and EPS Surprise Chart

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma /mitogen-activated protein kinase clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen’s KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts. Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. The indication in FL is approved under accelerated approval based on overall response rate.

Verastem announced it received FDA Breakthrough Therapy designation for VS-6766 with defactinib in recurrent low-grade serous ovarian cancer. Verastem’s market cap is calculated by multiplying VSTM’s current stock price of $0.43 by VSTM’s total outstanding shares of 200,677,979. Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of (“Regulation A”).

VSTM Verastem Inc

My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market’s returns over the past century! I think it’s a crying shame folks don’t know how powerful dividends are. Verastem has a short interest ratio (“days to cover”) of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Only 3.20% of the stock of Verastem is held by insiders. Only 8 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% blueberry markets review is a scam or legit broker compared to the previous 30 days. 20 people have searched for VSTM on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

High institutional ownership can be a signal of strong market trust in this company. MarketBeat has tracked 8 news articles for Verastem this week, compared to 1 article on an average week. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

Real-time analyst ratings, insider transactions, earnings data, and more. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits. Discuss news and https://day-trading.info/ analysts’ price predictions with the investor community. Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers.

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. 5 brokers have issued 1-year price objectives for Verastem’s stock. Their VSTM share price forecasts range from $3.00 to $6.00. On average, they predict the company’s share price to reach $4.25 in the next twelve months.